We support and invest in early stage, life science initiatives that share our vision.

We accelerate healthcare innovation through investment and partnerships. Because we believe data science has the potential to transform patient care, we are investing in early stage initiatives that share our vision.

Why Partner with us?

BioInfoGate understands investment as a collaborative partnership. We help nurture strategic projects by providing valuable in-kind resources and hands-on support.

  • Industry expertise in data and the life sciences
  • Network and connections in data science ecosystem
  • Opportunity to cross-fertilize ideas
  • Hands-on support from Bioinfogate team
  • Long-term commitment
  • Access to mentors and advisors

In sum, we appreciate and understand how much effort goes into starting a successful data driven company in the life sciences. If you are developing innovative intellectual property assets in the field of data science applied to therapeutic discovery, we want to hear from you.

We are looking for early stage startups, academic research teams or companies with novel uses of data in the life sciences. Our goal is to help promising research projects reach proof of concept and move their work from bench to bedside.

Areas of Interest

  • Big Data in Life Sciences
  • Analytics & Visualization
  • Pharmacogenomics
  • Synthetic Biology
  • Medical Technology
  • Diagnostics
  • Digital Health

Priority Therapeutic Areas

  • CNS
  • Oncology

Our Investment Criteria

  • Early Stage Proof of Concept
  • New Therapeutic Targets
  • Clear and Scalable Business Model
  • Data Science Talent
  • Data Science Approach

Recent Investments


QUIBIM SL, a biotechnology company specializing in advanced analysis of medical images, announced in December 2016 the closure of the first round of funding, with a total of 550,000 Euros. Funding came from Bioinfogate, as well as Tech Transfer UPV, AYCE Capital, and the company’s founders. QUIBIM, a spin-off of the Institute of Health Research La Fe, was founded in 2012 by Angel Alberich-Bayarri and Dr. Luis Martí Bonmatí following a long history of research and development. The startup has developed a platform for cloud-based medical image analysis, which can also be privately installed for hospitals and pharmaceutical companies developing clinical trials. Using X-ray images, echography, CT, MRI or PET scans, QUIBIM employs advanced analysis algorithms including GPU-based (graphics processing unit) processing, and big data and machine learning methodologies. QUIBIM’s software allows greater information for diagnoses and the early evaluation of response to pharmacological treatments.